MetaSignal Therapeutics Inc. (MST) is a private biopharmaceutical company developing innovative therapeutics to block cancer metastasis by focusing on the "driving forces" of cancer metastasis, hypoxia, altered cell metabolism and invasion-migration.  Cancer metastasis is a process that leads to the dissemination or spread of tumor cells at multiple sites and accounts for 90% of cancer mortality of patients.  Utilizing a biomarker-driven strategy, the company is targeting an unmet therapeutic need that is present in all major cancers.  MetaSignal has developed a rich pipeline of innovative programs to tackle cancer metastasis and the lead programs are at the clinical candidate selection stage.